Obermatt
See Similar Stocks →

Flags

Financial distress

Scilex

NAQ:SCLX · US80880W2052
PharmaceuticalsSmall

360° View

6
Price/Sales67
Price/Earnings—
Price/Book73
Dividend Yield1
Revenue Growth4
Profit Growth91
Capital Growth41
TSR 52w46
Leverage4
Liquidity15
Refinancing1
Combined25
Analyst Opinions1
Pro Holdings11
Opinion Changes50
Market Pulse45

Profile

CountryUSA
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Employees72
Websitescilexholding.com
ISINUS80880W2052
Last UpdateApr 2, 2026
Index & Theme
Chronic DiseasesNeurologyNeurosciencePain ManagementCentral Nervous SystemHealth CareMedicalPharmaceutical

Description

Scilex Holding Company acquires, develops and commercializes non-opioid pain management products for the treatment of acute and chronic pain. The company’s commercial products are: ZTlidoÒ (lidocaine topical system) 1.8%, a prescription lidocaine to…

Analysis

Scilex's 360° View rank of 6 places it among the weakest overall — better than 6% of its true peers.

It's growing solidly (61) and looks cheap versus peers (90). On safety it is highly leveraged (1), and the market shows muted sentiment (29). Taken together, its Combined rank of 25 reads as among the weakest overall.

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
67
—
—
—
Price/Earnings
—
—
—
—
Price/Book
73
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
90
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Scilex with its peers
Rigel Pharmaceuticals
NSQ:RIGL
66
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Contineum Therapeutics
NSQ:CTNM
80
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Xeris Pharmaceuticals
NSQ:XERS
70
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Karyopharm Therapeutics
NSQ:KPTI
6
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Kura Oncology
NSQ:KURA
30
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Lexicon Pharmaceuticals
NAQ:LXRX
28
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →